Literature DB >> 1600769

The acute effects of continuous positive airway pressure and oxygen administration on blood pressure during obstructive sleep apnea.

N J Ali1, R J Davies, J A Fleetham, J R Stradling.   

Abstract

We have measured blood pressure continuously with a digital artery blood pressure monitor in eight patients with severe obstructive sleep apnea (OSA) during 30 min each of wakefulness, OSA, OSA with added oxygen to keep saturation above 96 percent at all times (OSA+O2), and nasal continuous positive airway pressure (CPAP) therapy. Mean blood pressures were not different between wakefulness, OSA, OSA+O2, and CPAP, although the variability in blood pressure was significantly greater during OSA and OSA+O2 than during wakefulness and CPAP. The addition of oxygen did not attenuate the variability in blood pressure. Using multiple linear regression modeling to further dissect out the principal variables determining the postapneic blood pressure rise, we found that only apnea length (r2 = 0.28, p less than 0.0001) and pulse rate changes (r2 = 0.15, p less than 0.0001) remained significantly related to SBPmax, while hypoxemia did not. We found the same trends in the other variables SBPten, DBPmax, and DBPten. Hypoxemia made a small contribution to the size of DBPmax, although this was small by comparison with apnea length. We conclude that CPAP treatment of OSA does not lower mean blood pressure acutely, although it significantly reduces the large oscillations in blood pressure seen in patients with untreated OSA. The rise in blood pressure following each apnea is not primarily due to arterial desaturation but is related to apnea length and may be caused by increased sympathetic activity secondary to arousal.

Entities:  

Mesh:

Year:  1992        PMID: 1600769     DOI: 10.1378/chest.101.6.1526

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

Review 1.  Cardiovascular consequences of obese and nonobese obstructive sleep apnea.

Authors:  Kannan Ramar; Sean M Caples
Journal:  Med Clin North Am       Date:  2010-05       Impact factor: 5.456

Review 2.  Mechanisms of vascular damage in obstructive sleep apnea.

Authors:  Malcolm Kohler; John R Stradling
Journal:  Nat Rev Cardiol       Date:  2010-12       Impact factor: 32.419

Review 3.  Disorders of sleep: an overview.

Authors:  Leon Ting; Atul Malhotra
Journal:  Prim Care       Date:  2005-06       Impact factor: 2.907

Review 4.  Cardiovascular aspects of obstructive sleep apnoea and their relevance to the assessment of the efficacy of nasal continuous positive airway pressure therapy.

Authors:  R J Davies
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

Review 5.  Obstructive sleep apnoea.

Authors:  Sophie D West; Chris Turnbull
Journal:  Eye (Lond)       Date:  2018-02-02       Impact factor: 3.775

6.  Variables affecting the change in systemic blood pressure in response to nasal CPAP in obstructive sleep apnea patients.

Authors:  Junaid Malik; Christopher L Drake; David W Hudgel
Journal:  Sleep Breath       Date:  2008-03       Impact factor: 2.816

Review 7.  Obstructive sleep apnea and oxygen therapy: a systematic review of the literature and meta-analysis.

Authors:  Vanita Mehta; Tajender S Vasu; Barbara Phillips; Frances Chung
Journal:  J Clin Sleep Med       Date:  2013-03-15       Impact factor: 4.062

8.  Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea.

Authors:  Tarek A Dernaika; Gary T Kinasewitz; Maroun M Tawk
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

9.  Non-invasive beat to beat arterial blood pressure during non-REM sleep in obstructive sleep apnoea and snoring.

Authors:  R J Davies; J Crosby; K Vardi-Visy; M Clarke; J R Stradling
Journal:  Thorax       Date:  1994-04       Impact factor: 9.139

10.  The role of compliance with PAP use on blood pressure in patients with obstructive sleep apnea: is longer use a key-factor?

Authors:  I Bouloukaki; C Mermigkis; N Tzanakis; K Giannadaki; E Mauroudi; V Moniaki; E M Kallergis; S E Schiza
Journal:  J Hum Hypertens       Date:  2016-07-28       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.